Company
ReviR Therapeutics is a global, clinical-stage biotechnology company committed to discovering and developing innovative RNA-targeting small-molecule therapies for neurological diseases, inflammation and immunology (I&I) and oncology. ReviR was founded in 2021 by leaders in computational biology, RNA biology, genomics and drug discovery, with the aim of creating highly selective, effective and safe disease-modifying therapies. Its proprietary VoyageR™ platform integrates AI-enabled modelling, RNA structure and function analysis, genomic and transcriptomic data, and experimental validation systems, including iPSC models. The platform supports the full discovery and translation workflow, from target identification and molecule design to patient stratification and clinical development. ReviR’s lead programme, RTX-117, is in clinical development for Charcot-Marie-Tooth disease and vanishing white matter disease, while its potential in fibrotic diseases is also being explored.
Description
ReviR Therapeutics is a clinical-stage biotech company developing disease-modifying small-molecule therapy by combining artificial intelligence with RNA biology.
